ARTICLE | Clinical News
Macugen pegaptanib regulatory update
August 23, 2004 7:00 AM UTC
The FDA accepted for filing EYET and PFE's NDA for Macugen pegaptanib to treat exudative (wet) age-related macular degeneration (AMD). The NDA has Fast Track and Priority Review designations and a Dec...